Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,491,648
  • Shares Outstanding, K 46,614
  • Annual Sales, $ 77,060 K
  • Annual Income, $ -135,670 K
  • 60-Month Beta 1.21
  • Price/Sales 19.40
  • Price/Cash Flow N/A
  • Price/Book 5.48
Trade MIRM with:

Options Overview Details

View History
  • Implied Volatility 72.28% ( +5.99%)
  • Historical Volatility 42.37%
  • IV Percentile 76%
  • IV Rank 65.47%
  • IV High 96.12% on 10/18/23
  • IV Low 27.10% on 04/05/23
  • Put/Call Vol Ratio 1.43
  • Today's Volume 34
  • Volume Avg (30-Day) 103
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 2,837
  • Open Int (30-Day) 2,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.31
  • Number of Estimates 5
  • High Estimate -0.20
  • Low Estimate -0.50
  • Prior Year -0.99
  • Growth Rate Est. (year over year) +68.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.75 +15.32%
on 11/02/23
33.24 -3.73%
on 11/30/23
+3.58 (+12.60%)
since 11/01/23
3-Month
26.00 +23.08%
on 09/05/23
33.39 -4.17%
on 09/18/23
+5.56 (+21.03%)
since 09/01/23
52-Week
17.49 +82.96%
on 12/21/22
33.39 -4.17%
on 09/18/23
+13.72 (+75.05%)
since 12/01/22

Most Recent Stories

More News
Why Shares of Travere Therapeutics Are Slumping Thursday

A mixed trial could hurt a kidney drug's chances of full approval.

MIRM : 32.00 (-0.22%)
TVTX : 6.42 (+2.23%)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 16.67% and 3.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

MIRM : 32.00 (-0.22%)
YMAB : 6.16 (-0.81%)
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.

MIRM : 32.00 (-0.22%)
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ADPT : 4.70 (+7.31%)
MIRM : 32.00 (-0.22%)
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 0.6141 (-0.18%)
MIRM : 32.00 (-0.22%)
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...

MIRM : 32.00 (-0.22%)
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?

IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

IDYA : 31.63 (+0.57%)
MIRM : 32.00 (-0.22%)
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”)...

MIRM : 32.00 (-0.22%)
American Airlines, Emerson Electric fall; Triton, Chart rise

Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise

MIRM : 32.00 (-0.22%)
TRTN : 79.55 (-4.10%)
EMR : 90.12 (+1.37%)
TH.TO : 2.20 (+2.33%)
NATI : 59.98 (unch)
NCMI : 3.95 (-2.71%)
GTLS : 134.84 (+3.70%)
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior...

MIRM : 32.00 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 33.56
2nd Resistance Point 33.03
1st Resistance Point 32.51
Last Price 32.00
1st Support Level 31.46
2nd Support Level 30.93
3rd Support Level 30.41

See More

52-Week High 33.39
Last Price 32.00
Fibonacci 61.8% 27.32
Fibonacci 50% 25.44
Fibonacci 38.2% 23.57
52-Week Low 17.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar